Table 1 Baseline characteristics of patients allocated to the control group (glucose levels managed using the routinely used sliding scale) versus patients allocated to the experimental group (glucose levels managed using the automated algorithm)
Control (n = 29) | Experimental (n = 30) | |
|---|---|---|
Age | 61.0 (9.3) | 64.3 (7.7) |
BMI | 28.9 (5.2) | 30.6 (5.1) |
Gender | ||
Females | 10 (34.5) | 4 (13.3) |
Males | 19 (65.5) | 26 (86.7) |
ASA | ||
3 | 19 (65.5) | 26 (86.7) |
4 | 10 (34.5) | 4 (13.3) |
Diabetes complications | ||
Nephropathy | 3 (10.3) | 5 (16.7) |
Nephropathy + Neuropathy | 1 (3.4) | 1 (3.3) |
Nephropathy + Neuropathy + Retinopathy | 1 (3.4) | 0 (0) |
None | 24 (82.8) | 24 (80) |
Baseline glucose level | 166 (55.2) | 142.7 (35.8) |
Surgery type | ||
CABG | 17 (58.6) | 20 (66.7) |
CABG and valve repair | 5 (17.2) | 7 (23.3) |
Valve repair | 4 (13.8) | 2 (6.7) |
Aortic root replacement | 2 (6.9) | 1 (3.3) |
Atrial septal defect repair | 1 (3.4) | 0 (0) |
Cardioplegia type | ||
Saint-Thomas Cardioplegia Solution | 15 (51.7) | 21 (70) |
Custodial Cardiplegia Solution | 8 (27.6) | 6 (20) |
Delnido Cardioplegia Solution | 5 (17.2) | 3 (10) |
None | 1 (3.4) | 0 (0) |
Duration of aortic cross clamping | 96.6 ± 48.2 | 97.2 ± 37.8 |
Cardiopulmonary bypass time | 135.1 ± 60.3 | 128.8 ± 43.7 |